Profile: Xtrana, Inc. develops and markets nucleic acid-based tests for drug discovery, human & animal diseases, and genetic predisposition diseases. Our nucleic acid-based tests processes include nucleic acid-double or single stranded DNA & RNA captures from high volume & low concentration specimens, which results in buffer changes & volume reduction. The tightly bound nucleic acids are used to analyse & confirm results in both research & commercial applications.

The company has revenues of USD 1-5 Million, has ~20 employees. NASDAQ:XTRN (SEC Filings)